Introduction
============

Resistance to antimicrobial drugs is an increasingly important public health concern leading to increased mortality, morbidity, and cost of care for affected patients. Thus, discovery of novel drug targets against drug resistant pathogens is both timely and of utmost importance. However, development of new antimicrobial agents is both time-consuming and expensive, but the re-purposing of previously tested and/or approved drugs as antimicrobial therapeutic agents may be a potentially useful alternative ([@B5]). This review examines data supporting targeting of the thioredoxin system as a mechanism leading to broad spectrum antimicrobial activity against multiple species of bacteria, fungi, and eukaryotic parasites using drugs previously tested by the U.S. Food and Drug Administration (FDA).

Thioredoxins (TrxA, TrxC, Trx1, Trx2, and Trx3) are small redox proteins that possess a highly conserved active site (cys-x-x-cys) ([@B31], [@B32]) referred to as the "thioredoxin motif" which consists of four α-helices and five β-sheets ([@B32]). The thioredoxin system is an efficient disulfide reduction system, consisting of two proteins: thioredoxin, the flavoenzyme thioredoxin reductase (TrxR, Trr1, and Trr2), plus the reducing agent nicotinamide adenine dinucleotide phosphate (NADPH). These ubiquitous proteins are found in all forms of life and they, along with the glutathione/glutathione reductase (GSH/GR) are responsible for maintaining a reduced cellular environment ([@B31]).

Although highly conserved, there are notable differences in thioredoxin reductase. In humans and some protozoans, a high-molecular weight thioredoxin reductase (H-TrxR) is present while in bacteria, fungi, plants, and some protozoa, a low-molecular weight thioredoxin reductase (L-TrxR) is observed ([@B54]). While both forms contain a redox active disulfide adjacent to a flavin ring, the transfer of the reducing equivalents from the flavin ring to the protein substrate have distinct mechanisms. For an in-depth analysis on these differences, refer to the review by [@B91]. **Figures [1A,B](#F1){ref-type="fig"}** show the differences in structure and electron transfer between H-TrxR and L-TrxR. Together, these differences allow L-TrxR containing thioredoxin systems to be a potential antimicrobial target. To that end, we review the function of thioredoxin in bacteria, fungi, protozoa, and helminths, and examine some current thioredoxin system inhibitors as potential antimicrobial agents.

![**(A)** Example of the protein structure of the high (*Homo sapiens*) and low (*Escherichia coli*) molecular weight thioredoxin reductase. Shown are the flavin-adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADPH) binding domains, the 'central' domain and the C-terminal domain that provides the dimer interface and part of the active site. **(B)** Differential electron transfer between high and low molecular weight TrxR. **(C)** Chemical structures of the thioredoxin system inhibitors auranofin, ebselen, and PX-12. Panels **(A,B)** adapted from [@B51].](fmicb-09-00336-g001){#F1}

Global Functions of Thioredoxin
-------------------------------

The thioredoxin system functions as a potent reducer of disulfide bonds. Disulfide bond reduction is initiated by a nucleophilic attack of the first cysteine of the twin cysteine motif on the disulfide of the target protein leading to formation of a mixed disulfide bond between thioredoxin and the target protein. Subsequently, the second cysteine nucleophilically attacks the mixed disulfide, forming an intramolecular disulfide bond in thioredoxin fully reducing the target protein ([@B71]). In turn, thioredoxin is reduced by thioredoxin reductase using NADPH as source of electrons ([@B51]). In all organisms studied to date, the thioredoxin system plays an important role in keeping the intracellular compartment in a reduced state which has been shown to be important in preventing protein aggregation ([@B30]; [@B79]). Additionally, thioredoxin acts as a hydrogen donor for key enzymes involved in various cellular functions. Examples of these enzymes include ribonucleotide reductase, an essential enzyme during DNA synthesis ([@B69]), and methionine sulfoxide reductase which plays an important role in protein repair ([@B25]; [@B10]). Thioredoxin also is a hydrogen donor for phosphoadenosine-phosphosulfate reductase ([@B48]; [@B12]) which is implicated in sulfur assimilation, and required for *de novo* cysteine biosynthesis in fungi and many enteric bacteria ([@B25]; [@B73]).

Drug Characteristics
--------------------

Arguably the best studied inhibitor of the thioredoxin system is auranofin, a gold complex originally approved to treat rheumatoid arthritis ([@B8]). Although thioredoxin reductase may not be the sole target for auranofin ([@B83]), the drug is believed to inhibit this enzyme by irreversibly binding thiol and selenol groups on the enzyme ([@B22]). Ebselen is an organoselenium drug that acts as an antioxidant and an anti-inflammatory agent due to its GSH peroxidase-like activity ([@B57]; [@B76]), and is a potent bacterial TrxR inhibitor via its binding to the C-terminal active site cysteine residue ([@B52]). 1-Methylpropyl 2-imidazolyl disulfide (PX-12) irreversibly binds to the Cys73 cysteine residue that lies outside the conserved redox catalytic site of Trx1 ([@B40]). Initially tested as an antitumor drug, it was not approved due to lack of efficacy in human trials; although, it exhibited low toxicity ([@B68]). Like most commonly used antibiotics, the common side effects of auranofin and PX-12 include nausea, lack of appetite, diarrhea, and stomach cramps ([@B24]; [@B15]; [@B68]). Ebselen has not shown adverse effects at the recommended dose ([@B78]). Please see **Table [1](#T1){ref-type="table"}** for a list of pathogens these drugs have been tested against. For chemical structures of these inhibitors, see **Figure [1C](#F1){ref-type="fig"}**.

###### 

*In vivo* and *in vitro* studies of thioredoxin system inhibitors.

  Inhibitor   Pathogen                       Strain                                                                  Model               Reference
  ----------- ------------------------------ ----------------------------------------------------------------------- ------------------- -----------
  Auranofin   *S. aureus*                    MW2                                                                     *C. elegans*        [@B23]
  Auranofin   *S. aureus* (MRSA)             Sanger 252                                                              Murine---systemic   [@B27]
  Auranofin   *S. aureus* (MRSA)             132                                                                     Murine              [@B1]
  Auranofin   *C. neoformans*                Clinical isolate                                                        *C. elegans*        [@B82]
  Auranofin   *T. gondii*                    RH                                                                      Chicken embryo      [@B2]
  Auranofin   *G. lamblia*                   WB, 106, 1279                                                           Murine              [@B80]
                                             WB                                                                      Gerbil              
  Auranofin   *T. foetus*                    D1                                                                      Murine---vaginal    [@B33]
  Ebselen     *S. aureus*                    USA300                                                                  Murine---skin       [@B85]
  Ebselen     *E. coli*                      ZY-1                                                                    Murine---systemic   [@B97]
  Ebselen     *C. berghei*                   K173                                                                    Murine              [@B35]
  PX-12       *A. fumigatus*                 AF-dsRed                                                                Murine---corneal    [@B44]
  Auranofin   *S. aureus*                    MW2                                                                     *In vivo*           [@B23]
              *E. faecium*                   2421                                                                                        
              *K. pneumoniae*                77326                                                                                       
              *A. baumannii*                 ATCC 17978                                                                                  
              *P. aeruginosa*                PA14                                                                                        
              *Enterobacter* sp.             KCTC 2625                                                                                   
              *B. subtilis*                  PY 79                                                                                       
              *E. faecalis*                  MMH 594                                                                                     
              *C. albicans*                  SC5314 (CAN14)                                                                              
              *C. glabrata*                  ATCC 90030                                                                                  
              *Candida parapsilosis*         ATCC 22019                                                                                  
              *C. tropicalis*                ATCC 13803                                                                                  
              *C. neoformans*                KN99α                                                                                       
  Auranofin   *M. tuberculosis*              H37Ra                                                                   *In vivo*           [@B27]
              *B. subtilis*                  168, PY79                                                                                   
              *S. aureus* (MRSA)             Sanger 252, TCH1516, ST-59, A7819, PA, D712                                                 
                                             A5940, X18311, PC-3, HIP 5836                                                               
              *S. aureus*                    MSSA 29213                                                                                  
              *E. faecium* (VRE)             VRE8 WMC, VRE 12-15-19 UCLA                                                                 
              *E. faecalis*                  Belt                                                                                        
              *K. pneumoniae*                1100                                                                                        
              *A. baumannii*                 ATCC 19606, ATCC 17978, 5075                                                                
              *P. aeruginosa*                PA01, PA103                                                                                 
  Auranofin   *E. histolytica*               HM1:IMSS                                                                *In vivo*           [@B17]
  Auranofin   *P. falciparum*                3D7                                                                     *In vivo*           [@B74]
  Auranofin   *L. infantum*                  MHOM/TN/80/IPT1                                                         *In vivo*           [@B36]
  Auranofin   *T. brucei*                    449                                                                     *In vivo*           [@B50]
  Auranofin   *E. granulosus*                Clinical isolate                                                        *In vivo*           [@B9]
  Auranofin   *E. coli*                      ATCC 25922                                                                                  
              *S. aureus*                    ATCC 25923, USA300                                                      *In vivo*           [@B11]
              *Staphylococcus epidermidis*   ATCC 35984, ATCC 12228                                                                      
              MRSA                           Five clinical isolates                                                                      
  Auranofin   *P. aeruginosa*                n/a                                                                     *In vivo*           [@B28]
              *E. coli*                      n/a                                                                                         
              *S. aureus*                    USA300                                                                                      
              *S. cerevisiae*                USA400                                                                                      
  Auranofin   *C. albicans*                  CA-1 to CA-13                                                           *In vivo*           [@B90]
              *C. glabrata*                  CG-1 to CG-10                                                                               
              *Candida krusei*               QC                                                                                          
              *C. parapsilosis*              QC, CP-1 to CP-10                                                                           
              *C. neoformans*                CN-1 to CN-3                                                                                
              *Blastomyces dermatitidis*     BD-1 to BD-3                                                                                
              *Paecilomyces variotii*        QC                                                                                          
              *A. fumigatus*                 AF-1 to AF-3                                                                                
              *Rhizopus oryzae*              R-1 to R-3                                                                                  
              *S. apiospermum*               SA-1 to SA-7                                                                                
              *L. prolificans*               SP-1 to SP-6                                                                                
  Auranofin   *S. aureus*                    TCH1516                                                                 *In vivo*           [@B88]
  Auranofin   *T. gondii*                    RH                                                                      *In vivo*           [@B2]
  Auranofin   *C. albicans*                  SC5314                                                                  *In vivo*           [@B77]
  Ebselen     *E. coli*                      DHB4                                                                    *In vivo*           [@B52]
              *H. pylori*                    MSG6, MSG142, MR162                                                                         
                                             MRG193, NCTC11637, YS-16                                                                    
              *M. tuberculosis*              H37Rv                                                                                       
                                             Panel 3:24                                                                                  
                                             BTB98-310                                                                                   
  Ebselen     *S. aureus* (MRSA)             USA100, USA200, USA300                                                  *In vivo*           [@B85]
                                             USA400, USA500, USA700                                                                      
                                             USA800, USA1000, USA1100                                                                    
                                             ATCC 43300, ATCC BAA-44                                                                     
              Linezolid-resistant SA         NRS119                                                                                      
              Mupirocin-resistant SA         NRS 107                                                                                     
              Vancomycin-resistant SA        VRS1--VRS3a, VRS3b                                                                          
                                             VRS4--VRS10                                                                                 
              *S. epidermidis*               NRS101                                                                                      
              *S. aureus*                    ATCC 6538                                                                                   
  Ebselen     *B. subtilis*                  ATCC 6633                                                               *In vivo*           [@B26]
              *S. aureus*                    ATCC 29213                                                                                  
              *Bacillus cereus*              ATCC 14579                                                                                  
              *M. tuberculosis*              H37Rv                                                                                       
  Ebselen     *S. aureus*                    ATCC 25923                                                              *In vivo*           [@B66]
              *Staphylococcus simulans*      103P                                                                                        
              *E. coli*                      ATCC 25922                                                                                  
              *P. aeruginosa*                ATCC 258243                                                                                 
              *K. pneumoniae*                ATCC 700603                                                                                 
              *Aspergillus niger*            Filamentous                                                                                 
              *C. albicans*                  Yeast                                                                                       
  Ebselen     *E. coli*                      DHB4, ZY-1, ATCC 700926                                                 *In vivo*           [@B97]
                                             1139, 2219                                                                                  
              *K. pneumoniae*                322                                                                                         
              *A. baumannii*                 H, 361                                                                                      
              *P. aeruginosa*                1298, 9                                                                                     
              *Enterobacter cloacae*         431, 2301                                                                                   
  Ebselen     *S. cerevisiae*                AH109                                                                   *In vivo*           [@B7]
  Ebselen     *Aspergillus flavus*           ATCC MYA-3631                                                           *In vivo*           [@B61]
              *Aspergillus terreus*          ATCC MYA-3633                                                                               
              *Aspergillus nidulans*         ATCC 38163                                                                                  
              *C. albicans*                  ATCC 10231, 64124, MYA-2876, MYA-90819, MYA-1003, MYA-2310, ATCC 1237                       
              *C. glabrata*                  ATCC 2001                                                                                   
              *C. krusei*                    ATCC 6258                                                                                   
              *C. parapsilosis*              ATCC 22019                                                                                  
  Ebselen     *P. falciparum*                T~9~96                                                                  *In vivo*           [@B35]
  PX-12       *A. fumigatus*                 AF-bp                                                                   *In vivo*           [@B44]

Bacterial Thioredoxin
---------------------

In general, bacterial thioredoxin systems are encoded by a single thioredoxin reductase, and two thioredoxin genes. The best studied system is that of *Escherichia coli* which has two thioredoxins, a higher expressed Trx1 protein (encoded by *TrxA*) with greater electron donor efficacy and a less expressed TrxC which contains two additional c-x-x-c motifs at its N-terminus ([@B43]; [@B55]). As shown by gene deletion, neither of these thioredoxin genes are required for viability in *E. coli* ([@B70]). However, some bacteria, such as *Rhodobacter sphaeroides* ([@B63]), *Bacillus subtilis* ([@B75]), and *Anacystis nidulans* ([@B60]) require a bacterial thioredoxin gene for survival. Redundant to the thioredoxin system in many bacteria is the glutaredoxin system which was initially identified as an alternative hydrogen donor for ribonucleotide reductase in an *E. coli* thioredoxin mutant ([@B29]). Simultaneous disruption of both thioredoxin and glutaredoxin systems is often lethal for bacteria ([@B67]; [@B79]). To date, it appears most Gram-negative bacteria contain both a thioredoxin and GSH system while most Gram-positive bacteria contain only a thioredoxin system ([@B51]). This highlights the critical role of thiol-redox homeostasis for microbial growth and further underscores antimicrobial drug potential.

Bacterial thioredoxin function and gene regulation has been reviewed previously ([@B95]; [@B51]). Recent reports from animal studies have shed additional light on the important role of thioredoxin in bacterial pathogenesis. [@B13] propose that TrxA is essential for maintaining a highly reduced environment in the cytosol of *Listeria monocytogenes* providing a favorable environment for protein folding and subsequent activation. Furthermore, it was observed that TrxA is required for proper function of several key regulators, including (1) MogR, a DNA binding transcriptional repressor involved in flagella formation, and (2) PrfA, a member of the cAMP receptor protein (Crp) family of transcription factors which regulates several major virulence factors (ActA, LLO, and Hpt) of *Listeria*. Deletion of the TrxA gene in *Listeria* resulted in loss of motility and impairment of hemolytic activity greatly reducing virulence of this pathogen in mice.

Thioredoxin also has been shown to play a role in the virulence of *Helicobacter pylori* which uses secreted thioredoxin to reduce mucin molecules to their monomeric form decreasing mucin viscosity and allowing the organism to colonize as well as facilitating migration to the epithelial surface ([@B92]). Deletion of either the TrxA or TrxC genes in *H. pylori* impairs the organism's ability to colonize the stomach following oral bacterial challenge ([@B42]).

[@B49], while studying a *Mycobacterium tuberculosis* thioredoxin reductase (TrxB2) mutant, observed TrxB2 to be an essential thiol-reducing enzyme *in vitro*, and its deficiency lead to increased clearance of the bacterium during both the acute and chronic phases of infection. Importantly, TrxB2 depletion resulted in hyper-susceptibility to rifampin, a frontline anti-tuberculosis drug, suggesting that a thioredoxin inhibitor can be used in combination with other existing antibiotics for better control of bacterial infection. This could be of significant therapeutic value in treatment of multi-drug resistant bacteria when choice of available antibiotics is limited.

Auranofin has been tested in both Gram-positive and Gram-negative bacteria. Auranofin exhibited a lower minimum inhibitory concentration (MIC) for Gram-positive pathogens than for Gram-negative, likely due to (1) the presence of the redundant GSH system ([@B11]; [@B27]; [@B23]), and (2) the impermeability of the drug through the outer membrane ([@B83]). Using an *in vitro* enzymatic assay, [@B27] clearly demonstrated that auranofin inhibited both recombinant thioredoxin reductases of *M. tuberculosis* and *Staphylococcus aureus*, by reducing bacterial cellular free thiols, leading to compromised defense against oxidative stress.

Auranofin was also tested against medically relevant drug resistant pathogens collectively referred to as "ESKAPE" pathogens. This grouping includes *Enterococcus faecium*, *S. aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species. Auranofin was found to inhibit *S. aureus*, *E. faecium*, and *A. baumannii* in bacteriostatic fashion at the MIC, but bactericidal at higher concentrations ([@B23]). A number of studies using *S. aureus* have recognized auranofin as a potent antibacterial compound. Using an *in vivo Caenorhabditis elegans* infection model, auranofin was shown to be protective against *S. aureus*, *Enterococcus faecalis*, and *E. faecium* via apparent targeting of the thioredoxin system ([@B23]). Auranofin and other related gold-compounds also were shown to exhibit significant inhibition against methicillin-resistant *S. aureus* (MRSA) ([@B28]). Animal studies carried out using mouse models further demonstrate the potential usefulness of auranofin against cutaneous ([@B84]) and implant-associated biofilm ([@B1]) infections by MRSA.

Ebselen and ebselen analogs have bactericidal effects against MRSA, *E. coli*, and *H. pylori* by blocking electron transfer to thioredoxin ([@B52]). Similar to auranofin, ebselen is highly active against bacteria lacking GSH production, e.g., *S. aureus*, *H. pylori*, *M. tuberculosis*, and *Bacillus anthracis* ([@B52]; [@B26]), but less effective against Gram-negative bacteria ([@B66]). Simultaneous blockage of both thioredoxin and glutaredoxin systems has been explored by [@B97] using ebselen and silver nitrate for treatment of Gram-negative bacterial infection. These results demonstrated that silver in the presence of ebselen directly inhibited *E. coli* thioredoxin reductase, and rapidly depleted GSH resulting in elevated reactive oxygen species (ROS) production and impaired DNA synthesis leading to bacterial death. Additionally, combined treatment significantly improved survival from sepsis by *E. coli* during murine infection. In a recent study using *S. aureus* by [@B85], ebselen was demonstrated to greatly reduce (1) toxin (Panton--Valentine leukocidin and α-hemolysin) production, (2) biofilm formation *in vitro*, and (3) with topical treatment of skin infection significantly reduced bacterial loads accompanied with a decreased inflammatory response.

Fungal Thioredoxin
------------------

*Saccharomyces cerevisiae* contains both cytoplasmic and mitochondrial thioredoxin systems. Under normal growth conditions, cytoplasmic thioredoxins (Trx1 and Trx2) are both dispensable; however, simultaneous deletion of both thioredoxins slowed the rate of DNA synthesis leading to abnormal cell cycle ([@B58]). Thioredoxin has also been shown to function in a protective manner against ROS in *S. cerevisiae* ([@B41]; [@B59]) as well as medically important fungi such as *Candida albicans* ([@B16]) and *Aspergillus nidulans* ([@B87]). The yeast mitochondrial thioredoxin system, which includes a thioredoxin (Trx3) and thioredoxin reductase (Trr2), protects against oxidative stress generated during respiratory metabolism ([@B65]). However, it does not appear that this mitochondrial system can substitute for the cytoplasmic thioredoxin or glutaredoxin systems, as its presence does not ameliorate the slowing of the cell cycle when Trx1 and Trx2 genes are deleted ([@B18]). Fungal thioredoxin reductases are of the low molecular weight protein type with an overall folding structure similar to bacterial TrxR ([@B96]). Strains lacking Trr1 gene are hypersensitive to hydrogen peroxide, temperature sensitive for growth, and have an auxotrophic requirement for methionine ([@B53]; [@B64]). Trr1 is most likely essential in *C. albicans* as a true Trr1 gene knock out could not be created; however, heterozygous strains of *C. albicans* are more sensitive to oxidative stress and exhibit a decreased pathogenicity compared to the wild-type ([@B94]). Similarly, Trr1 was shown to be essential to *Cryptococcus neoformans* viability ([@B56]).

*In vitro* auranofin inhibited medically relevant *Aspergillus fumigatus*, *Candida tropicalis*, *Candida glabrata*, and *C. albicans*, and was shown to have high efficacy against fluconazole resistant *C. albicans* as well as the hard-to-treat fungal pathogens *Scedosporium apiospermum* and *Lomentospora prolificans* ([@B23]; [@B90]). Additionally, auranofin exhibited significant inhibition of *C. albicans* biofilm formation ([@B77]), and was shown to protect against *C. neoformans* infection in an *in vivo C. elegans* model ([@B82]).

Ebselen has been shown to be effective against *S. cerevisiae* as well as fluconazole-resistant *C. albicans* ([@B7]). Additionally, ebselen analogs are effective against *C. albicans* and *Aspergillus* spp. ([@B66]; [@B61]). A recent study by [@B81], demonstrated that ebselen regulates fungal GSH and ROS production, and is a potent antifungal drug against clinically relevant isolates of both *Candida* and *Cryptococcus* in a *C. elegans* infection model.

PX-12 was tested against the filamentous fungus *A. fumigatus*, and lead to increase fungal hyphae sensitivity to both H~2~O~2~ and neutrophil-mediated killing *in vitro.* Furthermore, topical PX-12 treatment significantly enhanced neutrophil-mediated fungal killing in infected mouse corneas ([@B44]).

Protozoa and Helminth Thioredoxin Systems
-----------------------------------------

Like bacteria, protozoans contain either a thioredoxin system or a combination of thioredoxin and GSH systems. *Entamoeba histolytica*, *Trichomonas vaginalis*, and *Giardia lamblia* all possess a thioredoxin system, consisting of thioredoxin (Trx), Trx peroxidase, and an L-TrxR ([@B34]; [@B14]; [@B4]; [@B46]). *Plasmodium falciparum* possesses both GSH/GR and Trx/TrxR redox systems ([@B38]; [@B62]; [@B39]); however, loss of TrxR results in loss of viability in this pathogen ([@B86]).

Genome sequencing of *Trypanosoma brucei* ([@B6]), *Trypanosoma cruzi* ([@B19]), and *Leishmania major* ([@B37]) demonstrated that trypanosomatids lack genes for GSH/GR and Trx/TrxR. Instead, they rely on trypanothione, a GSH derivate, and trypanothione reductase (TryR) to maintain disulfides in a reduced form ([@B20]; [@B21]).

TrxR also has been shown to be a virulence factor in *Toxoplasma gondii*. Deletion of *T. gondii* TrxR gene reduced the parasite's antioxidant capacity, invasion efficiency, and proliferation significantly prolonging the survival time of mice infected with the gene-knockout parasite as compared to the wild-type strain of parasite ([@B93]). Flatworms of the class Cestoda and Trematoda possess a single flavoenzyme for both thioredoxin and GSH, and is referred to as thioredoxin GSH reductase (TGR; [@B72]). *Schistosoma mansoni* depends totally on TGR for thiol redox homeostasis. Auranofin binds to TGR leading to reduced worm burdens *in vivo* ([@B3]). Inhibitors of TGR will not be covered further in this review.

The antimicrobial drug metronidazole (Flagyl) depends upon reduction by a flavoenzyme to become active. Resistance to this drug has been associated with changes in amounts of flavoenzymes produced by parasites ([@B89]; [@B47], [@B45]). Since metronidazole does not directly inhibit the thioredoxin system, it will not be discussed further in this review.

Auranofin has also been shown to be effective in protection against protozoa and helminthes. *E. histolytica* trophozoites were observed to be 10 times more sensitive to auranofin than to metronidazole ([@B17]). Auranofin blocked thioredoxin reductase in multiple strains of metronidazole resistant *G. lamblia*, as well as greatly reducing the number of trophozoites in the small intestine of orally challenged newborn and adult mice and gerbils ([@B80]). Auranofin also has been shown to have potent antimicrobial effects both *in vivo* and *in vitro* against *T. gondii* ([@B2]). Oral administration of auranofin for 4 days cleared *Tritrichomonas foetus* in a murine model of vaginal infection ([@B33]). Auranofin has also been shown to inhibit the growth of *P. falciparum* ([@B74]), the pro-mastigote stage of *Leishmania infantum* ([@B36]), the blood stream and procyclic stages of *T. brucei* ([@B50]), as well as *Echinococcus granulosus* larvae ([@B9]).

Treatment of protozoan and helminth infections with ebselen has not been widely explored. However, [@B35] reported that while ebselen blocked the growth of human *P. falciparum* at all stages including the invasion of erythrocytes by merozoites using highly synchronized cultures, treatment was ineffective against murine *Plasmodium berghei* in a mouse infection model.

Conclusion
==========

Thioredoxin is a ubiquitous redox protein found in all life forms. However, significant differences in the structure of thioredoxin reductase moieties vary among higher eukaryotes and microbes. Most importantly, all bacteria, helminths, fungi, and some protozoa contain a low molecular weight thioredoxin reductase. This differs from the high molecular weight enzyme found in mammals. Therefore, the thioredoxin system can be used as an ideal target for novel antimicrobial therapies. As drug resistance continues to grow and in the absence of introduction of new antimicrobials, the repurposing of currently available drugs may constitute a new and viable therapeutic approach.

Currently, FDA tested drugs targeting the thioredoxin system include PX-12, auranofin, and ebselen. These drugs have shown antimicrobial effects in a variety of organisms (**Table [1](#T1){ref-type="table"}**). The repurposing of these previously approved drugs could allow for better treatment options, including synergistic effects with existing antimicrobial drugs, against microbial infections.
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